Mezagitamab

Phase 3Monoclonal antibody

Takeda

Mezagitamab is one of 160 small molecule programs targeting Kidney Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

159

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney DiseaseRecruiting

Multiple MyelomaActive, not recruiting

Immune ThrombocytopeniaActive, not recruiting

Iga NephropathyActive, not recruiting

Immune Thrombocytopenic Purpura ( ITP )Recruiting

NephropathyActive, not recruiting

Kidney DiseasePhase 3

Recruiting

Multiple MyelomaPhase 1/Phase 2

Active, not recruiting

Immune ThrombocytopeniaPhase 3

Active, not recruiting

Iga NephropathyPhase 3

Active, not recruiting

Immune Thrombocytopenic Purpura ( ITP )Phase 3

Recruiting

NephropathyPhase 1

Active, not recruiting

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Mezagitamab

Takeda

Phase 3

2 2

Ninlaro

Takeda

Preclinical

18 3

Prolia

Amgen

Preclinical

5 4

Eliquis

Bristol-Myers Squibb

Preclinical

3 5

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

2 6

Nolvadex

AstraZeneca

Preclinical

1 7

Adriamycin

GGynecologic Oncology Group

Preclinical

9 8

Oncovin

EEastern Cooperative Oncology Group

Preclinical

8 9

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 10

Abecma

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 3Recruiting

Immune Thrombocytopenic Purpura ( ITP )

NCT06722235

Q3 2029

Phase 3Recruiting

Immune Thrombocytopenic Purpura ( ITP )

NCT06948318

Q1 2030

Phase 3Recruiting

Kidney Disease

NCT06963827

Clinical

Trials by Indication[1]

Multiple Myeloma2 trials

A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)

Terminated· Takeda logo

Takeda·Phase 1/2·NCT04776018·27 enrolled

A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)

Completed· Takeda logo

Takeda·Phase 1/2·NCT03439280·50 enrolled

Immune Thrombocytopenic Purpura ( ITP )2 trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants With Chronic Primary Immune Thrombocytopenia

Recruiting· Takeda logo

Takeda·Phase 3·NCT06722235·171 enrolled

A Phase 3, Open-label, Multicenter Continuation Trial to Evaluate the Long-term Safety and Efficacy of Mezagitamab Subcutaneous Injection in Adults With Chronic Primary Immune Thrombocytopenia

Recruiting· Takeda logo

Takeda·Phase 3·NCT06948318·150 enrolled

Nephropathy1 trial

A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy

Completed· Takeda logo

Takeda·Phase 1·NCT05174221·17 enrolled

Kidney Disease1 trial

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate Efficacy and Safety of Mezagitamab (TAK-079) in Study Participants With Primary IgA Nephropathy in Combination With Stable Background Therapy

Recruiting· Takeda logo

Takeda·Phase 3·NCT06963827·347 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Mezagitamab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mezagitamab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mezagitamab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: Takeda

Mezagitamab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q3 2029

Q1 2030

Trials by Indication[1]

Multiple Myeloma2 trials

Immune Thrombocytopenic Purpura ( ITP )2 trials

Nephropathy1 trial

Kidney Disease1 trial

References

Drug Info

Quick Facts

Related News